ConductScience.org, home

Paper39028186

Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations.

Heisler J and 4 others. MAbs, 2024. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations. Papers, record 39028186. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39028186

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Modulation of the high concentration viscosity of IgG1 antibodies using clinically validated Fc mutations.
PubMed
Journal
MAbs
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
1.37, provisional
iCite
Revised in PubMed
2026-04-30
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Heisler JJoelhttps://orcid.org/0000-0002-2703-3035
2Kovner DDaniel
3Izadi SSaeedhttps://orcid.org/0000-0003-4206-8559
4Zarzar JJonathan
5Carter PJPaul Jhttps://orcid.org/0000-0001-7854-062X

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
TrastuzumabMajor topic
OmalizumabMajor topic
Immunoglobulin Fc FragmentsMajor topic
Immunoglobulin GMajor topic
MutationMajor topic
Humans
Viscosity
Immunoglobulin Fab Fragments

Source PubMed

Download CSV of topics

References81

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133834944Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parameters.MAbs2021https://conductscience.org/library/papers/33834944PubMed
211160318Engineered antibodies with increased activity to recruit complement.J Immunol2001https://conductscience.org/library/papers/11160318PubMed
324737331Selective antibody intervention of Toll-like receptor 4 activation through Fc γ receptor tethering.J Biol Chem2014https://conductscience.org/library/papers/24737331PubMed
419250681Structural characterization of a human Fc fragment engineered for extended serum half-life.Mol Immunol2009https://conductscience.org/library/papers/19250681PubMed
536109838Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names.MAbs2022https://conductscience.org/library/papers/36109838PubMed
626849155Therapeutic Antibody Engineering To Improve Viscosity and Phase Separation Guided by Crystal Structure.Mol Pharm2016https://conductscience.org/library/papers/26849155PubMed
723744091Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).Protein Eng Des Sel2013https://conductscience.org/library/papers/23744091PubMed
817368483Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1.J Mol Biol2007https://conductscience.org/library/papers/17368483PubMed
938853585Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.MAbs2024https://conductscience.org/library/papers/38853585PubMed
1017875730Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.Cancer Res2007https://conductscience.org/library/papers/17875730PubMed
1125559441Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions.MAbs2015https://conductscience.org/library/papers/25559441PubMed
1219705420Specific interactions in high concentration antibody solutions resulting in high viscosity.J Pharm Sci2010https://conductscience.org/library/papers/19705420PubMed
1334747330Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.MAbs2021https://conductscience.org/library/papers/34747330PubMed
149231898Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library.J Mol Biol1997https://conductscience.org/library/papers/9231898PubMed
151560463Antibody framework residues affecting the conformation of the hypervariable loops.J Mol Biol1992https://conductscience.org/library/papers/1560463PubMed
1618723496Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.Mol Cancer Ther2008https://conductscience.org/library/papers/18723496PubMed
1733789155A review of Formulations of Commercially Available Antibodies.J Pharm Sci2021https://conductscience.org/library/papers/33789155PubMed
1826736022Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development.MAbs2016https://conductscience.org/library/papers/26736022PubMed
1926574392Long-Time-Step Molecular Dynamics through Hydrogen Mass Repartitioning.J Chem Theory Comput2015https://conductscience.org/library/papers/26574392PubMed
2033346034Machine Learning Feature Selection for Predicting High Concentration Therapeutic Antibody Aggregation.J Pharm Sci2021https://conductscience.org/library/papers/33346034PubMed

See all 81 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42533550Self-interaction nanoparticle spectroscopy predicts high-concentration viscosity of therapeutic IgG1 antibodies.MAbs2026https://conductscience.org/library/papers/42533550PubMed
41899522Biophysical and Structural Characterization of Antibody-Drug Conjugates.Cancers (Basel)2026https://conductscience.org/library/papers/41899522PubMed
41875154Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG1 antibodies.Proc Natl Acad Sci U S A2026https://conductscience.org/library/papers/41875154PubMed
40888155Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study.MAbs2025https://conductscience.org/library/papers/40888155PubMed
40775487Fifty years of monoclonals: the past, present and future of antibody therapeutics.Nat Rev Immunol2025https://conductscience.org/library/papers/40775487PubMed
40683793TREM2 and LAG-3 in cancer and Alzheimer's disease immunotherapy.Trends Pharmacol Sci2025https://conductscience.org/library/papers/40683793PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
IGHE3497PubTator's text mininghttps://conductscience.org/library/genes/3497NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39028186

GET https://conductscience.org/api/papers/v1/39028186/references?page=2